Search Results - "Bidoli, P."

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin by Bossi, P., Cortinovis, D., Fatigoni, S., Cossu Rocca, M., Fabi, A., Seminara, P., Ripamonti, C., Alfieri, S., Granata, R., Bergamini, C., Agustoni, F., Bidoli, P., Nolè, F., Pessi, M.A., Macchi, F., Michellini, L., Montanaro, F., Roila, F.

“…The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the…”
Get full text

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer by Gerber, D.E., Horn, L., Boyer, M., Sanborn, R., Natale, R., Palmero, R., Bidoli, P., Bondarenko, I., Germonpre, P., Ghizdavescu, D., Kotsakis, A., Lena, H., Losonczy, G., Park, K., Su, W -C, Tang, M., Lai, J., Kallinteris, N.L., Shan, J.S., Reck, M., Spigel, D.R.

“…Bavituximab is a monoclonal antibody that targets phosphatidylserine in the presence of β2 glycoprotein 1 (β2GP1) to exert an antitumor immune response. This…”
Get full text

Targeted therapies and immunotherapy in non-small-cell lung cancer by Cortinovis, D, Abbate, M, Bidoli, P, Capici, S, Canova, S

“…Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy…”
Get full text

Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience by Luciani, A., Toschi, L., Fava, S., Cortinovis, D., Filipazzi, V., Tuzi, A., Marra, A., Rossi, S., Rossi, A., Blasi, M., Violati, M., Sala, L., Agustoni, F., Bidoli, P., Zonato, S., Ferrari, D.

Get full text

Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC) by Reck, M., Paz-Ares, L., Pérol, M., Johnson, M., Pennell, N., Novello, S., Cappuzzo, F., Bidoli, P., Zimmermann, A., Lee, P., Sashegyi, A., Varea Menendez, R.

Get full text

Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial by Barni, S., Rosati, G., Zagonel, V., Pella, N., Banzi, M., Zampino, M.G., Di Bartolomeo, M., Rimassa, L., Marchetti, P., Maiello, E., Artioli, F., Ferrari, D., Labianca, R., Bidoli, P., Zaniboni, A., Sobrero, A., Iaffaioli, V., de Placido, S., Frassineti, L.G., Galli, F., Petrelli, F.

Get full text

Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial by Petrelli, F, Rosati, G, Banzi, M, Zampino, M G, Pella, N, Di Bartolomeo, M, Maiello, E, Bidoli, P, Ferrari, D, Rimassa, L, Labianca, R, Scartozzi, M, Lonardi, S, de Placido, S, Zaniboni, A, Sobrero, A, Frassineti, L G, Silvestris, N, Corsi, D, Galli, F, Barni, S

Get full text

Small cell lung cancer by Rosti, G., Bevilacqua, G., Bidoli, P., Portalone, L., Santo, A., Genestreti, G.

“…Small cell lung cancer accounts for 13–15% of all lung cancer worldwide. There has been a decrease in the number of cases, with no clear explanation, except…”
Get full text

Metformin and risk recurrence in resected stage II/III colon cancer (CC) patients (pts): subgroup analysis from the TOSCA trial by Di Bartolomeo, M., Rosato, G., Banzi, M., Pella, N., Zampino, M.G., Rimassa, L., Maiello, E., Marchetti, P., Lonardi, S., Labianca, R., Zaniboni, A., Sobrero, A., Ferrari, D., Bidoli, P., Iaffaioli, V., De Placido, S., Frassineti, L., Frustaci, S., Nicolini, M., Vernieri, C., Galli, F.

Get full text

FOLFOX4/XELOX in stage II–III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial by Zaniboni, A., Lonardi, S., Labianca, R., Di Bartolomeo, M., Rosati, G., Ronzoni, M., Pella, N., Banzi, M., Zampino, M.G., Pasini, F., Marchetti, P., Rimassa, L., Maiello, E., Bidoli, P., Cinieri, S., Barni, S., Ciuffreda, L., Beretta, G., Frontini, L., Rulli, E., Sobrero, A.

Get full text

Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective by Cortinovis, D., Alberti, P., Frigeni, B., Bidoli, P., Cavaletti, G.

Get full text

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study by Cazzaniga, M. E., Torri, V., Villa, F., Giuntini, N., Riva, F., Zeppellini, A., Cortinovis, D., Bidoli, P.

“…Background. Vinorelbine (VRB) and capecitabine (CAPE) are demonstrated to be active in pretreated metastatic breast cancer patients. Different studies have…”
Get full text

3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM) by Gregorc, V, Gaafar, R, Favaretto, A, Grossi, F, Jassem, J, Polychronis, A, Bidoli, P, Tiseo, M, O'Brien, M, Shah, R, Taylor, P, Novello, S, Muzio, A, Bearz, A, Badurak, P, Greillier, L, Fontana, F, Colombi, S, Lambiase, A, Bordignon, C

Get full text

3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial by Stahel, R.A, Dafni, U, Gautschi, O, Felip, E, Curioni-Fontecedro, A, Peters, S, Massutí, B, Cardenal, F, Aix, S.P, Früh, M, Pless, M, Popat, S, Kotsakis, A, Cuffe, S, Bidoli, P, Favaretto, A, Carcereny, E, Sanchez Ronco, M, Molina, M.A, Rosell, R

Get full text

Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study by Bidoli, P, Zilembo, N, Cortinovis, D, Mariani, L, Isa, L, Aitini, E, Cullurà, D, Pari, F, Nova, P, Mancin, M, Formisano, B, Bajetta, E

“…Background: Many patients with advanced non-small-cell lung cancer (NSCLC) do not tolerate cisplatin-based regimens because of its nonhemathological toxicity…”
Get full text

9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC by Finocchiaro, G, Santoro, A, Grossi, F, Bidoli, P, Favaretto, A, Clementi, L, Massey, D, Lorence, R, Cappuzzo, F

Get full text

6131 POSTER Evaluation of BRAF Mutational Status in Wild Type (WT) KRAS Metastatic Colon-Rectal Cancer (MCRC) Patients (pts) Treated With Cetuximab (C) – a Single Institution Experience by Cazzaniqa, M.E, Baronchelli, S, Bovo, G, Pellizzoni, D, Crosti, F, Giuntini, N, Villa, F, Cortinovis, D, Bidoli, P

Get full text

FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer by Cortinovis, D L, Andriani, F, Livio, A, Fabbri, A, Perrone, F, Marcomini, B, Pilotti, S, Mariani, L, Bidoli, P, Bajetta, E, Roz, L, Sozzi, G

“…Inactivation of the FHIT and TP53 genes is frequently observed in primary non-small cell lung cancers (NSCLC) and cell lines and may contribute to resistance…”
Get more information

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient by Negri, T, Casieri, P, Miselli, F, Orsenigo, M, Piacenza, C, Stacchiotti, S, Bidoli, P, Casali, P G, Pierotti, M A, Tamborini, E, Pilotti, S

Get full text

Drugs ten years later: epirubicin by Bonadonna, G, Gianni, L, Santoro, A, Bonfante, V, Bidoli, P, Casali, P, Demicheli, R, Valagussa, P

Get more information